Hormone status of in-situ cancer in BRCA1 and BRCA2 mutation carriers

Lancet

Volumn 351, Issue 9114, 1998, Pages 1487-

  Osin, Pinchas ^b   Crook, Tim ^b   Powles, Trevor ^b   Peto, Julian ^b   Gusterson, Barry ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TAMOXIFEN;

BREAST CANCER; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; ENDOCRINE FUNCTION; FEMALE; GENE MUTATION; GERM LINE; HETEROZYGOTE; HUMAN; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SHORT SURVEY;

EID: 0032537361     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(98)24020-7     Document Type: Article

References (5)

1. 1 Breast Cancer Linkage Consortium. The pathology of familial breast cancer: differences between breast cancer in carriers of BRCA1 and BRCA2 mutations and sporadic breast cancer. Lancet 1997; 349: 1505-10.
2. 2 Johannsson OT, Idvall I, Anderson C, et al. Tumour biological features of BRCA1-induced breast and ovarian cancer. Eur J Cancer 1997; 33: 362-71.
3. 3 Crook T, Crossland S, Crompton MR, Osin P, Gusterson BA. p53 mutation in BRCA1-associated familial breast cancer. Lancet 1997; 350: 638-39.
4. 4 Gretarsdottir S, Thorlacius S, Valgardsdottier R, et al. BRCA2 and p53 mutations in primary breast cancer in relation to genetic instability. Cancer Res 1998; 58: 859-62.
5. 5 Detre S, Saccani Jotti G, Dowsett MA. "Quick score" method for immunohistochemical semiquantitative validation for oestrogen receptor in breast carcinomas. J Clin Pathol 1995; 48: 876-78.